

AMENDMENTS TO THE SPECIFICATION

Please replace the legend for Figure 1 beginning on page 11, line 31 with the following amended legend:

-- FIG. 1 illustrates a polynucleotide expression pattern according to the present invention. The 137 polynucleotides that highly correlated with a resistance/sensitivity phenotype classification of the 23 breast cell lines for the protein tyrosine kinase inhibitor compound BMS-A are shown. Each row corresponds to a polynucleotide, with the columns corresponding to expression level in the different cell lines. Expression levels for each polynucleotide were normalized across all 23 breast cell lines such that the median is 0 and the standard derivation is 1. The expression levels greater than the median are shaded in red, ~~and those below the mean are shaded in green, while those at the mean are shaded in black~~. The individual polynucleotides encoding the protein tyrosine kinase biomarkers of the invention are indicated at the right (details of the biomarkers are also shown in the Table 2). The cell lines ~~labeled in red are classified as resistant, and those labeled in blue are have been classified as being sensitive or resistant~~ to BMS-A according to their IC₅₀ as provided in Table 1 --

Please replace the legend for Figure 7 beginning on page 14, line 4 with the following amended legend:

-- FIG. 7 The expression pattern of the 137 marker polynucleotides in 134 primary breast tumors. These 137 polynucleotides are highly correlated with a resistance/sensitivity phenotype classification of the 23 breast cell lines for the protein tyrosine kinase inhibitor compound BMS-A according to the present invention (as shown in FIG.1). Each row corresponds to a gene, with the columns corresponding to expression level in the different breast tumor samples. Expression levels for each polynucleotide were normalized across all 134 breast tumor samples such that the median is 0 and the standard derivation is 1. The expression levels greater than the median are shaded in red, ~~and those below the mean are shaded in green, while those at the mean are shaded in black~~. The order of individual polynucleotides encoding the protein tyrosine kinase biomarkers of the invention are the same as indicated in FIG.1. The expression pattern clearly shows that a group of primary breast tumors (as indicated by the arrow) highly expressed sensitive markers of protein tyrosine

kinase inhibitor compound of the invention. By contrast, another different group highly expressed resistant markers. --